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Abstract
Background: Prostate cancer (PCa) is very common and frequently metastasizes to the spine. However, PCa spinal
metastases were rarely reported in the literature. In this study, the outcome of therapies and prognostic factors
affecting surgical outcomes for patients with PCa spinal metastases are discussed to select the best candidates for
aggressive surgical resection.
Methods: All patients affected by the spinal metastatic PCa surgically treated at our spine tumor center were reviewed.
Overall survival was analyzed from the time of spinal surgery. A univariate survival analysis and a multivariate Cox
proportional hazard analysis to identify independent prognostic factors were carried out. The survival rate was estimated
by the Kaplan-Meier method, and differences were analyzed by the log-rank test. Factors with P values of 0.1 or less were
subjected to multivariate analysis for survival rate by multivariate Cox proportional hazard analysis.
Results: A total of 31 consecutive patients were identified. Of these, 29 underwent surgical resection. The median
survival time of all patients after their spinal surgery was 44.0 months. Visceral metastases, revised Tokuhashi scores
(0–8/9–11/12–15), Tomita scores (7–10/2–6), hormone status, and bisphosphonate treatment were suggested as the
potential prognostic factors through univariate analysis. As they were submitted to the multivariate Cox regression
model, visceral metastases and Tomita score were found as independent prognostic factors.
Conclusions: Patients without visceral metastases and a Tomita score no more than 6 are favorable prognostic factors
for PCa metastases in the mobile spine.
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Background
Prostate cancer (PCa) is the second leading cause of
cancer-related deaths worldwide currently, with an esti-
mated 238,590 new diagnoses and approximately 29,720
related deaths in the USA in 2013 alone [1]. The morbid-
ity has increased substantially recently in China, with an
estimated incidence of 10/100,000 in 2010 compared with
1.71/100,000 in 1993 [2]. Although most patients respond
to surgery or radiation well, more than 80 % of patients
with advanced prostate cancer develop bone metastases
later in their lives, with the spine being the most com-
monly affected site [3]. The incidence of skeletal-related
events, such as pathologic skeletal fractures, neurologic
deficit, and intractable pain, secondary to prostate meta-
static spinal lesions, raises considerable high risks on both
patients’ quality of life and their health-care costs as with
other osteolytic metastases [4].
In most cases, bone pain in newly diagnosed metastatic
PCa is responsive to lowering testosterone to castrate
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levels (termed “castration sensitive”), and mild spinal cord
compression responds well to external beam radiation
therapy [5]. However, vertebral compression fractures and
segmental instability, along with progressive neurologic
deficits and para- or tetraplegia, collectively make op-
erative intervention mandatory [6]. Several studies have
shown that surgical treatment options are both import-
ant and effective for these patients [7–9]. However, all
surgical procedures of metastatic spinal disease remain
palliative by definition, and thus, clinicians are still
hesitant to choose surgery when faced with vertebral
metastases.
Therefore, it is necessary to perform a systematic ana-
lysis of all patients operated for metastatic PCa in our
hospital to evaluate the life expectancy and prognosis
which may help to select the best candidates for aggres-
sive surgical resection.
Methods
A retrospective review was performed on all patients
treated at our spine tumor center from April 2002 to
March 2012 for surgical treatment of spinal metastases.
During this period, 31 consecutive patients were histologi-
cally confirmed with PCa with metastases to the spine. All
of them were evaluated by multidisciplinary consultants to
provide therapeutic strategy, and the indications for surgi-
cal intervention were rapidly progressive neurological de-
terioration and pathologic skeletal fracture with the life
expectancy of more than 6 months. Permission from the
hospital ethics committee was obtained before commen-
cing this study, and an informed consent was required
from all patients or their legal guardians.
Of the 31 patients, 2 patients did not undergo surgical
treatment. One patient was due to the life expectancy of
less than 6 months, and the other is because osteoblastic
lesions did not destroy the stabilization of the spine. In this
regard, a total of 29 patients were included in this study.
Medical records of all patients are retrospectively retrieved
for clinical and operative reports, radiographic images, and
pathology reports. Data collected regarding primary PCa
included age at initial diagnosis, Gleason score, preopera-
tive serum PSA, and treatment modalities, including sur-
gery, radiation, and/or chemotherapy/hormonal therapy.
Data collected regarding the spinal metastases included
the following: age at diagnosis of spinal metastases;
Karnofsky performance score (KPS) which was recorded
just before surgery; presenting signs and symptoms, includ-
ing neurological function quantified by the Frankel grading
system; visceral metastases; location; local treatment with
cisplatin or methotrexate; bisphosphonate treatment;
adjuvant therapy (radiotherapy and/or chemotherapy); and
clinical scores, including Tomita scores [10], revised
Tokuhashi scores [11], and Crnalic prostate scores [8].
Before surgery, patients were examined with X-rays for
the affected spinal segments, computed tomography (CT)
of the involved vertebra, and magnetic resonance (MR)
imaging focused on the affected spinal segment to moni-
tor the extensiveness of the metastatic process and spinal
canal involvement. A systemic search for other metastases
was performed including abdominal sonography and chest
X-ray to detect pulmonary metastases. A selective 18F-flu-
deoxyglucose positron emission tomography is performed
to increase sensitivity and specificity to detect other meta-
static lesions according to patients’ informed decision.
Postoperative survival as a function of time was de-
fined as the interval from the date of spine surgery to
death or until July 2014 for alive patients and expressed
using the Kaplan-Meier method. The log-rank test was
used in univariate survival analysis to identify inde-
pendent variables that could predict prognosis. Clinical
experience and statistical analysis were used to decide
whether continuous variables should be categorized.
Factors with P values ≤0.10 were subjected to a multivari-
ate model for survival rate by multivariate Cox propor-
tional hazard analysis. P values ≤0.05 were considered
statistically significant. All statistical calculations were per-
formed by PASW Statistics, version 19.0.
Results
The study population included 29 consecutive patients,
with a median age of 71 (range 59–83) years. A sum-
mary of all variables tested by log-rank test is provided
in Table 1. Fifteen out of 29 patients were with a mean
duration of 21.5 (range 1–83) months from diagnosis of
PCa to spinal metastases, and the spinal metastases were
the initial manifestation of PCa in the remaining 14 pa-
tients. The diagnosis of spinal metastases was upon initial
examinations and pathological examination at our institu-
tion. There were 20 hormone-naïve patients including 14
patients with spinal metastases as the initial manifestation
of PCa and 6 patients who previously underwent prosta-
tectomy and did not receive hormonal therapy.
Most of our patients (27/29) have a similar symptom
that localized pain, along with radiating pain, was first
to occur and progressive neurological defects occurred
afterwards. Acute pathologic skeletal fracture was the
first symptom of the remaining 2 patients. Symptoms
of night pain, muscle weakness, and even paraplegia were
the most common reasons for patients to see doctors.
After surgery, localized back pain disappeared in all pa-
tients and Frankel scores at postoperative 6 months were
significantly improved by at least one level compared with
the preoperative scores (P < 0.05) (Table 2).
For patients who had more than one metastatic lesion
of the spine, operations were performed depending on
the degree of the spinal compression. Other osteolytic
lesions which did not lead to spinal compression were
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treated by percutaneous vertebroplasty (PVP). There were
no specific differences in surgical management specific to
PCa compared to the metastases from other tumors. Cur-
ettage and reconstruction of the spine were performed in
all cases. In thoracic and lumbar metastases, dorsal spinal
decompression and fixation was the standard surgical
technique. Fixation was achieved by transpedicular screws
and rods in 24 patients. Reconstruction was achieved by a
titanium mesh cage placement in 10 patients and by
cement-wire construct placement in 14 patients. In
cervical metastases, a ventral/dorsal/combined (1/3/1)
approach of decompression was performed, with stable-
angle plate osteosynthesis in the ventral approach, trans-
pedicular screws in the dorsal approach, and both in the
combined approach.
Bisphosphonate was used after surgery in 16 cases, with
incadronate disodium at a dose of 10 mg in 500-ml normal
saline intravenous infusion 2 h once a month for post-
operation 2 years. Thirty-one percent (n = 9) of the sample
sustained one or more postoperative complications, in-
cluding pulmonary infection, incision infection, cerebro-
spinal fluid infection, and lower extremity deep venous
thrombosis. One patient died within the first 30 days of
surgery because of postoperative cerebrospinal fluid infec-
tion. By the end of the study period, 18 patients were still
alive. The median survival time of all patients after their
spinal surgery was 44 (range 1–80) months, and the me-
dian survival time for survivors was 26 (range 14–80)
months. The 1-year overall survival was 89.7 %, 2-year
overall survival was 74.4 %, and 5-year overall survival was
19.7 %.
Univariate analysis of prognostic factors
The univariate analysis of the prognostic factors affecting
survival time is shown in Table 1. The factors such as vis-
ceral metastases, revised Tokuhashi scores, hormone sta-
tus, and bisphosphonate treatment showed the significant
effect for the patients’ overall survival in the univariate
analysis. In our series, patients without visceral metastases
had a better survival rate (P = 0.016). Among the possible
prognostic factors, the difference of overall survival rate
between patients with better revised Tokuhashi scores and
the worse ones was statistically significant (P = 0.048). Pa-
tients with hormone-naïve disease earned a longer life
than those with hormone-refractory disease (P = 0.049),
and the use of bisphosphonate treatment also effected the
survival period (P = 0.011). No significant difference was
found in other factors of age, tumor location, KPS, number
of vertebral metastases, number of extraspinal metastases,
Table 1 Univariate analysis of the prognostic factors affecting
survival










Present/not present 7/22 0.016*
Number of vertebral metastases
1/2/≥3 9/1/19 0.505
Number of extraspinal metastases
0/1–2/≥3 19/2/8 0.920
Preoperative Frankel score





















Hormone-naïve 1 means patients with spinal metastases as the initial
manifestation of PCa. Hormone-naïve 2 means patients who previously
underwent prostatectomy and did not receive hormonal therapy
*P value less than 0.1 for the multivariate analysis
Table 2 Frankel grade during follow-up




E 2 3 3
D 8 12 16
C 13 10 6
B 4 4 3
A 2 0 0
aThis patient died 1 month after surgery due to postoperative cerebrospinal
fluid infection
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hormone status 2, Tomita scores, Crnalic prostate scores,
preoperative Frankel score, preoperative PSA, urinary and
bowel continence, and history of PCa.
Multivariate analysis of prognostic factors
Univariate analysis suggested that the potential prognostic
factors were visceral metastases, revised Tokuhashi scores
(0–8/9–11/12–15), Tomita scores (7–10/2–6), hormone
status, and bisphosphonate treatment. They were submit-
ted to the multivariate Cox regression model for analysis
of overall survivals. The risk of death was significantly
decreased in patients with a Tomita score of 6 or less
compared with patients with a Tomita score of 7 or more.
The hazard ratio was 0.008 (95 % confidence interval
(CI) 0.000–0.743) for survival (P = 0.037). The risk of
death was significantly decreased in patients without
visceral metastases compared with patients with visceral
metastases. The hazard ratio was 199.232 (95 % CI 2.615–
15,180.426) for survival (P = 0.017). The Kaplan-Meier
curves of survival for Tomita score and visceral metastases
are shown in Fig. 1. The result of multivariate analysis
showed that revised Tokuhashi scores, the method of hor-
monal therapy, hormone status, and bisphosphonate treat-
ment were not independent prognostic factors for overall
survival. Details are listed in Table 3.
Discussion
More comprehensive testing methods for the early diag-
nosis of PCa and more effective treatments, such as
transurethral resection of the prostate (TURP) or andro-
gen deprivation therapy, have led to the favorable long-
term survival of patients with PCa. Nowadays, only a
few series in the literature focus on the therapeutic out-
comes and prognostic factor related to metastatic spinal
PCa [7–9, 12, 13] and there is no report from developing
countries. China’s, as the biggest developing country,
views on disease and the relative backward economic level
result in some differences about the patient composition
of metastatic PCa from those in developed countries. So,
we presented this study to add more information on the
treatments of spinal metastases secondary to PCa.
As spinal metastases from PCa are radiosensitive [14],
whether to apply a surgical intervention to metastatic
disease is always controversial. Surgical treatment for
metastatic spinal disease always strive for the maximum
palliative effect, including relieving pain and restoring the
function and stability of the spine, with a minimum of op-
erative mortality [7, 9, 15]. In our study, localized pain and
radiating pain were presented in all patients and disap-
peared in all these patients after surgery. Thirteen of 19
non-ambulatory patients regained their ambulatory ability,
but 1 patient experienced symptom deterioration because
of other level compressions. It means that the improve-
ment of ambulatory capability could be maintained until
other spinal cord compressions occurred. Therefore, the
benefit of surgical procedures on patients with paraplegia
caused by PCa metastases is apparent not only to patients
themselves but also to society, because many patients
Fig. 1 Kaplan-Meier curves of OS for a preoperative Tomita score and b visceral metastases
Table 3 Multivariate analysis of the prognostic factors affecting
survival
Factor HR (95 % CI) P
Tomita scores 0.008 (0.000–0.743) 0.037*
Visceral metastases 199.232 (2.615–15,180.426) 0.017*
Revised Tokuhashi scores 0.294
Revised Tokuhashi scores (1) 1.271 (0.039–41.351) 0.893
Revised Tokuhashi scores (2) 0.235 (0.028–1.967) 0.182
Hormone status 0.532 (0.062–4.596) 0.566
Bisphosphonate treatment 0.093 (0.005–1.631) 0.104
HR hazard ratio, CI confidence interval
*P values less than 0.05 were considered statistically significant
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received restoration of their ability to care for themselves.
However, 2 patients who presented with complete paraly-
sis preoperation for more than 2 weeks did not regain
their ambulatory ability. Therefore, it is limited to improve
the degree of neurological function for patients presented
with complete paralysis.
Age and Karnofsky performance status
The impact of age and preoperative KPS on predicting
survival after surgery for PCa spinal metastases is still
contradictory. Crnalic et al. [8] reported KPS as a strong
predictor of survival, and Ju et al. [9] reported that age
younger than 65 years was associated with increased risk
of postoperative complications, whereas both of those
were not related to survival in our study according to the
univariate analysis. In our opinion, age and KPS, consid-
ered as the general condition, may be controlled properly
by an increased monitored anesthesia care, surgical ex-
perience, and surgical techniques [16]. In the present
study, metastases occurred in patients aged 71 years old
(range 59–83), which was older than those presented pre-
viously [7–9, 12, 13]. Furthermore, patients presented with
severely impaired KPS (≤50) were more than other studies
[7–9, 12, 13].
The relatively old patient age and low KPS in our
study may be attributed to the size of the cohort, the
underdeveloped testing methods in China, and the nega-
tive attitude of Chinese people to seek medical advice. In
addition, insufficient health insurance in China may be
another reason. All these would count for late diagnosis
and reduce patients’ survival. In facing the patients with
old age and/or low KPS, the most important thing is to
evaluate their tolerance to surgical treatment. Our ex-
perience is that old age or low KPS is not the surgical
contraindication. If the patient can well tolerate the sur-
gical operation and anesthesia, there was no difference
between patients with low KPS and those with high KPS.
Metastatic burden
The bone and visceral spread and the extent and number
of bone metastases have been accepted as predictive fac-
tors for the patient’s survival [8, 12]. We found an associ-
ation between the presence of visceral metastases and
decreased survival according to multivariate analysis. The
maximum frequency of spine involvement occurred in
smaller prostate tumors (4–6 cm) as compared with the
maximum spread to the lung (6–8 cm) and liver (>8 cm)
[3]. Therefore, visceral metastases, presented with heavier
metastatic burden than spine metastases, developed in the
late stage of PCa. We agree with Crnalic et al.’s opinion
[8] that the presence of visceral metastases will further
depress their tolerance to surgery and make them suscep-
tible to complications, consequently having a potentially
negative effect on survival.
In the present study, metastatic lesions usually are pre-
sented multiple (20 cases), which is in accordance with
previous studies [14, 17]. Furthermore, 3 of the remaining
9 cases were treated before 2006, in which year we did not
have PET-CT and would not find other metastases.
Although the number of vertebral metastases was not an
independent factor for overall survival according to the
univariate analysis, the presence of multiple metastases
may significantly influence surgical planning regarding the
level of reconstruction [9].
Androgen deprivation therapy
Androgen deprivation therapy is the gold standard for
advanced PCa and can prolong the survival of men with
advanced PCa. Hormonal treatment can be applied in
receptor-positive prostate cancer patients [18]. The
result of our univariate analysis revealed that patients
with hormone-naïve disease had a better prognosis
compared to hormone-refractory ones, which is in ac-
cordance with previous studies [7, 8]. However, multi-
variate analysis revealed that it was not an independent
prognostic factor. It may be attributed to the small size
of the cohort, whereas, in our opinion, patients with
hormone-naïve disease present at an earlier phase of
metastatic PCa progression and are usually in good gen-
eral condition. Accordingly, we still regard patients with
hormone-naïve disease as potentially suitable candidates
for surgery [9].
Bisphosphonates
Osteolytic and osteoblastic lesions were found in most
radiographic images and operative reports in this study,
which is in accordance with Michaelson and Smith’s study
[19]. The bisphosphonates were used to inhibit osteoclast
activity by cellular mechanisms that affect osteoclast
attachment, differentiation, and survival and to reduce
osteoclast activity indirectly through effects on osteoblasts.
In our department, bisphosphonate had not been used
until 2007. In this study, 16 patients had received regular
bisphosphonate treatment after surgery, and their survival
were longer than others according to the univariate
analysis. This makes our study being the first one to in-
vestigate postoperative effect of bisphosphonates in
prolonging the survival time of the patients with spinal
metastases secondary to PCa [20–22]. Moreover, to our
knowledge, the antiangiogenic effects and antitumoral
activity of bisphosphonates can also contribute to restrain
the growth of tumors [23]. Therefore, bisphosphonate
treatment has been an integral component of the current
treatment concept of spinal metastases in our hospital
and, importantly, the use of bisphosphonates must be bal-
anced with their complications [24].
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Prognosis scores
We evaluated the prognosis scores of Tomita, revised
Tokuhashi, and Crnalic for life expectancy, and the re-
sults suggested that the Tomita scoring system indicated
prognosis properly according to multivariate analysis.
Nowadays, various scoring systems have been proposed
to estimate which patients with spinal metastases would
benefit most from surgery, and the histological type of pri-
mary tumor was placed on an important position. More-
over, Crnalic and his colleagues [8] presented a score for
predicting survival particular for metastatic PCa. However,
we agree with Enkaoua et al. [25] who thought it is a
drawback to apply prognosis scores completely in an acute
clinical situation, and to each retrospective study, it was
challenging to assess all parameters of the score accur-
ately, on account of the shortage of characteristics. Thus,
we suggest that scoring systems may help but cannot be
used as the only criteria in decision-making a surgery.
Although our study is a detailed analysis carried out for
spinal metastases from PCa and has described surgical
outcomes in a consecutive series, it has some limitations.
First, it is a retrospective investigation which results in a
certain degree of missing records and lack of a control
group. Second, the patients are limited to only metastatic
spinal PCa at a single spine tumor center within a re-
stricted time period, and the incidence in China is lower
than that of developed countries. Therefore, the sample
size of our study is not big. While recognizing these limi-
tations, it is hoped that this study may serve as a baseline
for future prospective investigations. Our future studies
will aim to enroll larger groups of PCa-only patients in
clinical trials in a prospective research design.
Conclusions
With the significant improvements in surgical experi-
ences and expertise in dealing with different metastases
problems, we suppose age and KPS are not the key
points to impact postoperative survival. Patients with-
out visceral metastases and a Tomita score no more
than 6 are favorable prognostic factors for PCa metasta-
ses in the mobile spine.
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